Patent intelligence · US
US 12310965
Treatment of cancer utilizing an identified adenosine fingerprint
Treatment of cancer utilizing an identified adenosine fingerprint
Patent details — US 12310965
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 27, 2025
- Expiration
- May 22, 2045
- Applicant
- Arcus Biosciences, Inc.
- Claims
- 8
- CPC classes
- A61K, A61K31/506, A61K31/706, A61K31/7076
Quick answer
US 12310965 (Treatment of cancer utilizing an identified adenosine fingerprint) is held by Arcus Biosciences, Inc.. Status: granted. Granted May 27, 2025. Expires May 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arcus Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/506, A61K31/706, A61K31/7076, A61K45/06, A61P
More from Arcus Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12415854
Antibodies to TIGIT
granted -
US 12410170
2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds
granted -
US 12384773
Thiazole compounds and methods of use thereof
granted -
US 12281136
Crystalline forms of a CD73 inhibitor and uses thereof
granted -
US 12226425
Inhibitors of ARG1 and/or ARG2
granted -
US 12195447
Azolopyrimidine for the treatment of cancer-related disorders
granted -
US 12168023
Inhibitors of adenosine 5′-nucleotidase
granted
Frequently asked questions
What is US patent 12310965?
US 12310965 (Treatment of cancer utilizing an identified adenosine fingerprint) is held by Arcus Biosciences, Inc.. Status: granted. Granted May 27, 2025. Expires May 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12310965?
Arcus Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 12310965 expire?
Our index shows an expiration date of May 22, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.